According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “
A number of other research firms have also recently commented on VNDA. Brean Capital set a $24.00 target price on Vanda Pharmaceuticals and gave the company a buy rating in a research note on Monday. Piper Jaffray Cos. set a $19.00 target price on Vanda Pharmaceuticals and gave the company a buy rating in a research note on Saturday, October 1st. Jefferies Group started coverage on Vanda Pharmaceuticals in a research note on Thursday, October 6th. They issued a buy rating and a $23.00 target price on the stock. Finally, JMP Securities increased their target price on Vanda Pharmaceuticals from $18.00 to $22.00 and gave the company a market outperform rating in a research note on Friday, August 26th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Vanda Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $20.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 17.32 on Tuesday. The firm’s market capitalization is $749.68 million. The firm’s 50-day moving average price is $16.14 and its 200 day moving average price is $11.81. Vanda Pharmaceuticals has a one year low of $6.91 and a one year high of $18.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.12. The firm had revenue of $36.02 million for the quarter, compared to analysts’ expectations of $36.03 million. Vanda Pharmaceuticals had a negative net margin of 31.85% and a negative return on equity of 22.51%. The business’s quarterly revenue was up 30.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. On average, equities analysts anticipate that Vanda Pharmaceuticals will post ($0.61) earnings per share for the current fiscal year.
In other Vanda Pharmaceuticals news, insider James E. Flynn sold 1,120,461 shares of the company’s stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $16.56, for a total transaction of $18,554,834.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James E. Flynn sold 547,886 shares of the company’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $15.66, for a total transaction of $8,579,894.76. The disclosure for this sale can be found here. Company insiders own 8.45% of the company’s stock.
A number of hedge funds have recently bought and sold shares of VNDA. Acrospire Investment Management LLC acquired a new stake in Vanda Pharmaceuticals during the first quarter valued at about $102,000. Bank of Montreal Can purchased a new stake in Vanda Pharmaceuticals during the second quarter worth $132,000. UBS Asset Management Americas Inc. raised its stake in Vanda Pharmaceuticals by 10.9% in the second quarter. UBS Asset Management Americas Inc. now owns 16,300 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 1,600 shares in the last quarter. Paloma Partners Management Co purchased a new stake in Vanda Pharmaceuticals during the second quarter worth $192,000. Finally, Jane Street Group LLC purchased a new stake in Vanda Pharmaceuticals during the second quarter worth $200,000. Institutional investors and hedge funds own 86.06% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.